Trajan Scientific and Medical (Trajan) continues to expand their technical and research capabilities, announcing a landmark agreement with academia and government in Australia today.
Trajan’s latest strategic collaboration with the University of Adelaide, supported by the South Australian Government, sees the realization of a research and development and manufacturing hub based on a new generation of specialty glass products for the global science and medical equipment market.
The hub will help scientists in the University’s Institute for Photonics and Advanced Sensing (IPAS) and the School of Physical Sciences commercialize their research into products that ultimately benefit human health and wellbeing.
The products have the potential to be utilized in a wide range of medical and scientific applications including genetic testing, biomarker discovery and detection, environmental analysis, food safety testing, testing for drugs of abuse and therapeutic drug monitoring.
Chief Executive Officer of Trajan, Stephen Tomisich says Trajan’s goal is for the hub to become a global centre of excellence for advanced photonics technologies.
“I anticipate that, through Trajan’s ability to present the world class photonics capabilities on the global stage, there will be many additional flow-on benefits. Partnering with Trajan essentially enables the commercialization of IPAS research discoveries, ensuring our work is applied to real-world situations - a hugely exciting outcome with almost unlimited potential,” Mr Tomisich said.
Professor Mike Brooks, Deputy Vice-Chancellor (Research), University of Adelaide adds: “Trajan’s skills in advanced manufacturing - including processes and systems, quality control, and logistics – combined with our research expertise and facilities, will enable transition of research outputs from the University and its partners into commercial manufacturing.”
Trajan’s global operations and customer base, partnered with the international standing IPAS enjoys as a centre of excellence in photonics and specialty glass technologies, means this collaboration will provide an incredible global platform to promote Australia.
Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements - especially those that can lead to portability, miniaturization and affordability.
Photo (L-R): Mr Stephen Tomisich, Chief Executive Officer, Trajan Scientific and Medical, Professor Mike Brooks, Deputy Vice-Chancellor (Research), University of Adelaide, The Hon Kyam Maher, Minister for Manufacturing and Innovation, Government of South Australia, and Professor Andre Luiten, Director, Institute for Photonics and Advanced Sensing.
Photo (L-R): Professor Mike Brooks, Deputy Vice-Chancellor (Research), University of Adelaide and Mr Stephen Tomisich, Chief Executive Officer, Trajan Scientific and Medical.
Photo (L-R): Professor Andre Luiten, Director, Institute for Photonics and Advanced Sensing, Professor Mike Brooks, Deputy Vice-Chancellor (Research), University of Adelaide and Mr Alastair Dowler, Technical Officer, Institute for Photonics and Advanced Sensing.
University of Adelaide Press Release
Media Contact Information
Trajan Scientific and Medical
+61 (0) 3 9837 4200
PR Consultancy: LBPR
+61 (0) 429 976 718
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.